The purpose of this study is to learn if vinflunine can shrink or slow the growth of cancer in patients with advanced or metastatic stomach cancer who have progressed on a prior treatment with a fluoropyrimidine or taxane-containing chemotherapy regimen. The safety of this treatment will also be studied.

Inclusion Criteria:

• Patients with locally advanced or metastatic gastric adenocarcinoma, including adenocarcinoma of the gastroesophageal junction who have progressed on a fluoropyrimidine or taxane-containing regimen in any combination in one prior first line treatment.
• EGOC performance status of 0,1 or 2
• Men and women, 18 years of age and older

Exclusion Criteria:

• Patients having received more than one previous systemic chemotherapy regimen in any setting.
• Major abdominal surgery within 2 months or any other surgery under general anesthesia within 4 weeks
• Unresolved occlusive or sub-occlusive intestinal disease or any significant chronic intestinal disease (e.g. ulcerative colitis)
• Prior radiation to >=30% of the bone marrow and/or radiation within 4 weeks prior to enrollment
• Acute or chronic hepatitis
• Known HIV infection
• A marked baseline prolongation of QT/QTc interval (e.g., repeated demonstration of a QTc interval >450 ms
• A history of additional risk factors for Torsade de Pointes (e.g., heart failure hypokalemia, family history of Long QT Syndrome)